Qaialdo: Uses, Dosage & Side Effects
Prescription-only oral suspension supplied at a strength of 10 mg/ml, dispensed under the brand name Qaialdo for use in adults and, where authorised, children as directed by a qualified prescriber.
Qaialdo is a prescription-only (Rx) medicinal product supplied as an oral suspension at a strength of 10 mg per millilitre. Because it is a liquid formulation, Qaialdo allows accurate, individually adjusted dosing in millilitres, making it suitable for patients who cannot swallow solid dosage forms – including young children, elderly patients, people with swallowing difficulties (dysphagia) and those receiving enteral feeding. The prescribing physician determines the specific indication, dose and duration of treatment for each individual patient based on their diagnosis, body weight, age, kidney and liver function, and concomitant illnesses. This evidence-based overview explains how oral suspensions such as Qaialdo work, how the prescribed dose should be measured and administered, how to recognise and respond to side effects, and how to store the medicine safely. For the official, product-specific prescribing information, always consult the Patient Information Leaflet (PIL) or Summary of Product Characteristics (SmPC) supplied with your medication and follow your prescriber's instructions.
Quick Facts: Qaialdo
Key Takeaways
- Qaialdo is a prescription-only oral suspension containing 10 mg of active substance per millilitre, which means every 1 ml delivers 10 mg, every 2.5 ml delivers 25 mg, and every 5 ml delivers 50 mg.
- The bottle must be shaken vigorously for at least 10 seconds before each dose; otherwise the active ingredient can settle at the bottom and the early doses will be too weak while later doses are too strong.
- Always measure Qaialdo with the oral syringe, dosing cup or graduated spoon supplied with the medicine – kitchen teaspoons vary in volume and can under- or over-dose the patient by up to 50%.
- Do not use Qaialdo if you are hypersensitive (allergic) to the active substance or any of the excipients; tell your doctor about all other medicines, supplements and herbal products you take to avoid drug interactions.
- Store Qaialdo as described on the carton – typically at room temperature or in the refrigerator – keep the bottle tightly closed, out of reach of children, and do not use after the expiry date or the in-use shelf life stated in the patient leaflet.
What Is Qaialdo and What Is It Used For?
Qaialdo is supplied as an oral suspension, a pharmaceutical formulation in which fine solid particles of the active drug substance are dispersed – but not dissolved – in a liquid vehicle, typically a sweetened, flavoured aqueous base. Oral suspensions are chosen when an active ingredient is poorly soluble in water, when a large or variable dose needs to be administered, or when the target patient population (for example infants, young children, frail older adults or people with swallowing difficulties) cannot reliably take solid dosage forms such as tablets or capsules.
The stated strength of 10 mg per millilitre (10 mg/ml) means that every 1 ml of the well-shaken suspension contains 10 milligrams of the active substance. This concentration allows clinicians to prescribe precise, individually tailored doses that can be adjusted in small increments, which is especially important in paediatrics, geriatrics and in patients with impaired organ function. Because small volume differences translate into meaningful dose differences, correct measurement with a calibrated oral device is a core part of safe Qaialdo therapy.
Qaialdo is classified as a prescription-only medicine (Rx). This legal classification reflects regulatory assessment that the product requires diagnosis, dose selection, monitoring or follow-up by a qualified healthcare professional. Before prescribing Qaialdo, your doctor will consider your medical history, current medications, allergies, age, weight, kidney and liver function, and any other clinical factors that may influence the benefit-risk balance of treatment. Do not take Qaialdo that has been prescribed for someone else, and do not share your Qaialdo with another person, even if they appear to have similar symptoms.
The authorised therapeutic use of Qaialdo – that is, the medical conditions for which it is approved – is set out in the regulatory documents issued by the medicines agency in the country where the product is marketed (for example the European Medicines Agency, the U.S. Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency, Swissmedic, Health Canada or the Australian Therapeutic Goods Administration). Your prescriber will have selected Qaialdo for your specific clinical situation on the basis of that authorised indication and current clinical guidelines. For the exact, product-specific indication you should consult:
- The Patient Information Leaflet (PIL), also known as the package insert, which is included inside every Qaialdo carton.
- The Summary of Product Characteristics (SmPC) or prescribing label, available through the relevant national medicines regulator.
- The instructions given by your prescriber, who will usually also record the indication on the prescription or label dispensed by the pharmacy.
Oral suspensions in general offer several clinical and practical advantages compared with solid dosage forms. They allow flexible weight-based dosing (for example, mg per kilogram of body weight), which is the standard approach in paediatric medicine and in several adult indications such as infection, oncology, neurology and some endocrine disorders. They can be administered via nasogastric or gastrostomy feeding tubes when clinically appropriate, and they are often absorbed faster than equivalent tablets because the active ingredient does not need to disintegrate first in the stomach. On the other hand, liquid formulations require strict attention to shaking, measuring, storage and shelf life – failing to follow the instructions can lead to subtherapeutic dosing (and treatment failure) or supratherapeutic dosing (and increased side effects).
The 10 mg/ml concentration provides a clear, easy-to-calculate relationship between volume and dose: 1 ml = 10 mg, 2.5 ml = 25 mg, 5 ml = 50 mg, and so on. This simplifies the calculation of weight-based paediatric doses and minimises the risk of arithmetic error. However, the same feature means that small measurement errors – for example using a 5 ml teaspoon when 2.5 ml was intended – will double the delivered dose. Always use the calibrated oral syringe or dosing cup supplied with the medicine.
What Should You Know Before Taking Qaialdo?
Contraindications
Qaialdo must not be used in patients with known hypersensitivity (allergy) to the active substance or to any of the inactive ingredients (excipients) listed in the Patient Information Leaflet. An allergic reaction to a previous dose – including hives (urticaria), widespread rash, facial or throat swelling (angioedema), wheezing, severe dizziness, fainting, or anaphylaxis – is an absolute contraindication to further use.
In addition to the primary allergy contraindication, the Summary of Product Characteristics may list specific clinical situations in which Qaialdo should not be used or should be used only with special caution. These commonly include, depending on the active substance:
- Severe impairment of kidney or liver function in which safe drug clearance cannot be assured.
- Concomitant use of certain medicines that produce dangerous pharmacological interactions (for example additive central nervous system depression, QT-interval prolongation, or elevated risk of bleeding).
- Presence of a medical condition for which the active ingredient is known to be harmful (for example certain cardiac arrhythmias, uncontrolled seizures, active gastrointestinal bleeding or severe electrolyte disturbances).
- Age limits defined by the authorised indication – Qaialdo may not be suitable for infants under a certain age or may require a reduced dose in older adults.
Your prescriber will review these formal contraindications against your individual medical history before prescribing Qaialdo. If you are uncertain whether any of them apply to you, check with your doctor or pharmacist before starting treatment.
Warnings and Precautions
Seek immediate medical attention if, at any time during Qaialdo treatment, you experience difficulty breathing, swelling of the lips, tongue or throat, severe dizziness, rapid drop in blood pressure, widespread rash or fainting. These can be signs of a serious allergic reaction (anaphylaxis), which is a medical emergency. Stop taking Qaialdo and contact your local emergency number immediately.
Before starting Qaialdo, tell your doctor about all of the following:
- Chronic diseases: Kidney disease (including reduced estimated glomerular filtration rate, or eGFR), liver disease (hepatic impairment), heart failure, arrhythmias, diabetes, asthma, gastrointestinal ulcers, bleeding disorders, autoimmune disease, recent surgery or any ongoing infection may influence the dose, the choice of medication or the intensity of monitoring.
- Previous drug reactions: Any previous allergic or hypersensitivity reaction to a medicine (especially to products containing the same active substance or a related compound), or any non-allergic intolerance such as persistent nausea, rash or liver enzyme elevations.
- Medicines and supplements: All prescription and over-the-counter drugs, herbal products, vitamins, minerals, recreational drugs and alcohol. Some combinations can reduce effectiveness or greatly increase the risk of adverse events.
- Special populations: If you are pregnant, think you might be pregnant, are planning pregnancy, or are breastfeeding; if the patient is a child or an older adult with multiple comorbidities; or if you are scheduled for surgery or anaesthesia.
During treatment, follow the monitoring schedule your prescriber recommends. This may include periodic blood tests (for example to check kidney function, liver enzymes, blood cell counts or electrolytes), blood pressure or heart-rate measurement, or symptom-based follow-up visits. Do not skip these appointments, even if you feel well, because some adverse effects are only detectable through laboratory monitoring.
Use in Children and Adolescents
Oral suspensions are frequently used in paediatric practice because they allow accurate weight- or body-surface-area-based dosing and can be swallowed by children who cannot take tablets. Whether Qaialdo is authorised for use in children, and from what age, is defined in the product information. Do not give Qaialdo to a child or adolescent outside the authorised indication without explicit instruction from a paediatrician or the prescribing physician. When using Qaialdo in children:
- Always measure the dose with the supplied paediatric oral syringe, which is calibrated in millilitres.
- Double-check the dose calculation, especially if the child's weight has changed recently, and re-confirm with the prescription label.
- Administer the suspension slowly into the side of the mouth (between cheek and gum) rather than squirting it onto the back of the tongue, to minimise gagging and aspiration risk.
- Never refer to medicine as "sweets" or "candy"; store Qaialdo in a locked cupboard out of reach of siblings.
Use in Older Adults
Older adults often have age-related reductions in kidney and liver function, a higher burden of concomitant medication (polypharmacy), and a higher baseline risk of falls, dehydration, electrolyte disturbances and cognitive impairment. These factors can alter how Qaialdo is absorbed, distributed, metabolised and excreted, and can increase the likelihood of side effects at a given dose. Your prescriber may therefore start Qaialdo at a lower dose and titrate cautiously ("start low, go slow"), and may schedule closer monitoring during the first weeks of treatment.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant or are planning pregnancy, tell your doctor before starting Qaialdo. Whether Qaialdo can be used safely during pregnancy depends on the specific active substance, the stage of pregnancy and the clinical indication. Your prescriber will weigh the potential benefit of treating your condition against any potential risk to the developing foetus. Some medicines are safe throughout pregnancy, others are avoided in the first trimester, and a few must be discontinued entirely because of teratogenic risk. If you become pregnant during Qaialdo therapy, do not stop the medicine abruptly on your own – contact your prescriber as soon as possible so that a safe plan can be made.
If you are breastfeeding, discuss with your doctor whether you can continue to nurse while taking Qaialdo. Many medicines pass into breast milk in small amounts that are harmless to the infant, but some substances can reach clinically relevant levels in milk and affect the baby. Your doctor or pharmacist can consult evidence-based lactation resources (such as LactMed or the UK Drugs in Lactation Advisory Service) to give you an individualised recommendation.
Driving and Operating Machinery
Depending on the active substance, Qaialdo may cause drowsiness, dizziness, blurred vision, impaired concentration or slower reaction times. Do not drive, operate heavy machinery or perform other safety-critical activities until you know how Qaialdo affects you, particularly during the first few days of treatment, after a dose increase or when combined with alcohol or other sedating medicines.
Important Information About Excipients
In addition to the active substance, Qaialdo oral suspension contains several inactive ingredients (excipients) that are needed to keep the formulation stable, palatable and safe. Depending on the specific formulation, these excipients may include preservatives, sweeteners, flavouring agents, thickeners, wetting agents, pH buffers and water. Some excipients that commonly appear in oral suspensions require special attention:
- Sugars (e.g., sucrose, sorbitol, glucose): Relevant if you have diabetes, hereditary fructose intolerance, sucrase-isomaltase deficiency or glucose-galactose malabsorption; sorbitol can also have a mild laxative effect at higher doses.
- Parabens or benzoate preservatives: Can cause hypersensitivity reactions (sometimes delayed) in sensitive individuals.
- Sodium: A "low sodium" statement may appear if the dose contains less than 1 mmol (23 mg) sodium – important for patients on a strict sodium-controlled diet.
- Ethanol (alcohol): Even small amounts can be relevant for children, pregnant or breastfeeding women, people with liver disease or patients recovering from alcohol dependence.
Check the excipient list in your Qaialdo Patient Information Leaflet and ask your pharmacist if you are unsure whether any of these components may affect you.
How Does Qaialdo Interact with Other Drugs?
Drug interactions fall into two broad categories. Pharmacokinetic interactions change how Qaialdo is absorbed, distributed, metabolised or excreted – for example, a co-administered medicine may induce or inhibit liver cytochrome P450 (CYP) enzymes, alter gastric pH, modify intestinal transport proteins (such as P-glycoprotein), or compete for elimination by the kidneys. Pharmacodynamic interactions occur when two medicines act on the same physiological system in an additive, synergistic or antagonistic way, even if they are handled by the body independently. Both categories are relevant for Qaialdo.
Below is a general framework of medication categories that frequently interact with oral medicines like Qaialdo. The specific relevance of each category depends on the active substance in your bottle, so always confirm the exact list with your pharmacist or the patient information leaflet.
| Interaction Category | Examples | Why It Matters |
|---|---|---|
| CYP enzyme inducers | Rifampicin, phenytoin, carbamazepine, St. John's wort, phenobarbital | Can accelerate breakdown of the active substance, reducing its effectiveness and potentially causing treatment failure. |
| CYP enzyme inhibitors | Clarithromycin, erythromycin, azole antifungals, ritonavir, grapefruit juice | Can slow the breakdown of the active substance, raising blood levels and increasing the risk of dose-dependent side effects. |
| Central nervous system depressants | Benzodiazepines, opioids, sedating antihistamines, alcohol, some antiepileptics | Additive sedation, drowsiness and respiratory depression if Qaialdo has CNS-active effects. |
| Anticoagulants and antiplatelets | Warfarin, dabigatran, rivaroxaban, apixaban, aspirin, clopidogrel | Increased risk of bleeding, especially if Qaialdo affects clotting factors, platelet function or gastrointestinal mucosa. |
| QT-prolonging medicines | Some antiarrhythmics, macrolide antibiotics, antipsychotics, certain antidepressants | Additive prolongation of the cardiac QT interval may increase the risk of life-threatening arrhythmias (Torsades de pointes). |
| Nephrotoxic medicines | NSAIDs, aminoglycosides, some contrast agents, ciclosporin, tacrolimus | Combined kidney stress can cause acute kidney injury; renal function may need closer monitoring. |
| Hormonal contraceptives | Combined oral contraceptive pill, progesterone-only pill, contraceptive patch, ring, implant | Some medicines reduce contraceptive effectiveness; additional contraceptive measures may be needed. |
| Antacids and absorption modifiers | Proton pump inhibitors, H2-blockers, calcium- or magnesium-containing antacids, iron, multivitamins | Can bind or alter absorption of the active substance; dosing may need to be separated by several hours. |
Minor and Clinically Unlikely Interactions
Many interactions listed in prescribing information have limited clinical relevance when the combination is used at normal doses for short periods in otherwise healthy patients. For example, a single dose of a common cold preparation may interact theoretically with many oral medicines but rarely causes symptomatic problems. Nevertheless, polypharmacy (multiple medicines at once), older age, impaired organ function, recent dose changes and narrow therapeutic-index drugs all push interactions from theoretical to clinically meaningful. When in doubt, ask a pharmacist: community pharmacists are trained to screen full medication lists for drug-drug and drug-food interactions free of charge.
Food, Drink and Lifestyle Interactions
Some Qaialdo-type oral suspensions should be taken on an empty stomach, others with food to reduce gastric irritation, and a few require avoidance of specific foods such as grapefruit juice, dairy products or alcohol. The patient information leaflet will specify the correct timing for your product. In general:
- Grapefruit juice inhibits intestinal CYP3A4 and can markedly increase blood levels of many medicines – avoid unless your prescriber confirms it is safe.
- Alcohol can add to sedation, increase stomach irritation and stress the liver; limit or avoid alcohol during treatment.
- Dairy products and calcium supplements can bind certain medicines (for example tetracyclines, quinolones, bisphosphonates) and reduce absorption; separate intake by at least 2 hours if advised.
- Herbal products – particularly St. John's wort, ginkgo, ginseng, kava and high-dose fish oil – can interact unpredictably with prescription medicines. Report every herbal and "natural" product to your pharmacist.
Ask your pharmacy to print a current list of all your prescriptions, or use a digital medication-management app. Update the list every time a medicine is added, changed or stopped, and bring it to each medical appointment. This simple habit prevents a large proportion of avoidable drug interactions and medication errors.
What Is the Correct Dosage of Qaialdo?
Qaialdo is supplied at a strength of 10 mg/ml, which means that the dose in milligrams and the dose in millilitres are linked by a simple factor of 10. Common prescribed doses translate into the following volumes:
| Volume (ml) | Delivered Dose (mg) | Typical Measuring Device |
|---|---|---|
| 0.5 ml | 5 mg | 1 ml paediatric oral syringe |
| 1 ml | 10 mg | 1 ml or 5 ml oral syringe |
| 2.5 ml | 25 mg | 5 ml oral syringe |
| 5 ml | 50 mg | 5 ml oral syringe or dosing cup |
| 7.5 ml | 75 mg | 10 ml oral syringe or graduated cup |
| 10 ml | 100 mg | 10 ml oral syringe or graduated cup |
Adults
For adult patients, the starting dose and maintenance dose of Qaialdo are prescribed according to the authorised indication and the patient's body weight, comorbidities and co-medications. In many conditions an initial titration is used: the dose is increased stepwise over days or weeks to reach the target dose, reducing the risk of early side effects and allowing the physician to identify the lowest effective dose. Do not increase the dose on your own, and do not double the next dose to compensate for a missed one.
Children and Adolescents
Qaialdo's 10 mg/ml strength is particularly useful in paediatrics because doses are typically calculated in mg per kilogram of body weight. For example, a 20 kg child prescribed 1 mg/kg per dose would receive 20 mg = 2 ml of Qaialdo per dose. Several safety principles apply whenever Qaialdo is given to a child:
- Re-calculate the dose at each weight check: Children grow quickly, and a dose that was correct three months ago may no longer match current body weight.
- Always use the paediatric oral syringe: Kitchen spoons and general household measures are inaccurate.
- Give the dose slowly, in small aliquots, into the side of the mouth. This reduces choking and improves the amount swallowed.
- Do not add Qaialdo to a full bottle of formula or a full meal unless specifically instructed; an unfinished bottle means an unfinished dose.
- Record each administration on a dosing diary, especially when more than one caregiver is involved, to avoid double-dosing.
Elderly Patients
Older adults may require a reduced starting dose and slower titration because of reduced drug clearance and a narrower therapeutic window. The prescriber may also schedule more frequent blood tests during the first weeks of treatment. Encourage older patients to use a weekly pill organiser or dosing diary and to contact their pharmacist if they notice new symptoms such as confusion, falls, unusual bleeding or changes in appetite.
Renal and Hepatic Impairment
If you have kidney disease or liver disease, your dose of Qaialdo may need to be reduced, or the interval between doses extended, to prevent drug accumulation. Your doctor will determine the appropriate adjustment based on laboratory values such as estimated glomerular filtration rate (eGFR), serum creatinine, bilirubin, alanine aminotransferase (ALT) and international normalised ratio (INR), where relevant.
Missed Dose
If you miss a dose of Qaialdo, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume the regular schedule. Do not take a double dose to make up for the missed one. If you are uncertain what to do, or if you have missed more than one dose, contact your prescriber, pharmacist or nurse for advice.
Overdose
If you have taken more Qaialdo than prescribed, or if a child has accidentally swallowed the suspension, seek medical advice immediately. Contact your local emergency number, poison information centre or the nearest emergency department, and bring the bottle and the carton with you so that the medical team can identify the active substance, the strength and the volume potentially ingested. Symptoms of overdose depend on the active ingredient but can include severe drowsiness, confusion, irregular heartbeat, breathing difficulties, seizures or coma. Treatment of overdose is supportive and may include monitoring of vital signs, activated charcoal (if ingestion was recent), intravenous fluids and specific antidotes where available.
How to Use the Oral Suspension
Correct preparation and administration of Qaialdo oral suspension is essential for achieving the prescribed dose safely:
- Read the label. Confirm the patient's name, the medicine name (Qaialdo), the strength (10 mg/ml), the dose in millilitres and the number of doses per day.
- Shake the bottle vigorously for at least 10–15 seconds before every dose. A suspension that is not well shaken will deliver too little active ingredient at first and too much at the end of the bottle.
- Open the bottle using the child-resistant cap, press down firmly and turn.
- Fit the supplied oral syringe or adaptor. Insert the tip into the bottle adaptor or hold the dosing cup at eye level on a flat surface.
- Draw up or pour the exact prescribed volume in millilitres. Double-check against the prescription label.
- Administer the suspension by mouth. For adults: swallow directly. For infants and children: slowly release the syringe contents into the inside of the cheek, not the back of the throat, to prevent choking.
- Offer a small drink of water afterwards (if the leaflet allows) to rinse any residue from the mouth.
- Rinse the oral syringe or cup with clean water, shake dry and store with the medicine.
- Replace the cap tightly on the bottle immediately after dosing.
Never transfer Qaialdo to another container, and never mix it with hot food or drinks unless your prescriber or pharmacist tells you to do so – heat can degrade the active substance, and large-volume food may be left unfinished, resulting in an incomplete dose.
What Are the Side Effects of Qaialdo?
The exact adverse-effect profile of Qaialdo is determined by its active substance and dose; it is described in detail in the Patient Information Leaflet. Health authorities classify side effects by frequency using standardised categories derived from clinical trial and post-marketing data. The table below presents a generic frequency framework that applies to most oral prescription medicines – refer to the product-specific leaflet for the exact list of reactions reported for Qaialdo.
Very Common
May affect more than 1 in 10 people
- Mild gastrointestinal effects such as nausea, reduced appetite or soft stools, especially during the first days of treatment.
- Altered taste sensation (dysgeusia) or a slight feeling of dry mouth related to the suspension's flavouring and excipients.
- Mild tiredness or headache that usually improves as the body adjusts to the medication.
Common
May affect up to 1 in 10 people
- Diarrhoea, constipation, abdominal discomfort or flatulence.
- Mild skin reactions such as localised rash, itching or transient flushing.
- Dizziness or mild changes in blood pressure on standing up.
- Difficulty sleeping, vivid dreams or transient mood changes (depending on active substance).
Uncommon
May affect up to 1 in 100 people
- More pronounced hypersensitivity reactions, including widespread urticaria (hives) or localised angioedema (swelling of lips, eyelids or tongue).
- Elevated liver enzymes (ALT, AST) detected on routine blood tests, usually asymptomatic and reversible.
- Changes in blood cell counts (for example mild anaemia or low white-cell count).
- Photosensitivity or increased skin reaction to sunlight.
Rare
May affect up to 1 in 1,000 people
- Severe allergic reactions (anaphylaxis) with breathing difficulty, throat swelling and collapse.
- Severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), characterised by painful widespread rash, blistering and peeling.
- Marked liver injury (drug-induced liver injury, DILI) with jaundice, dark urine, pale stools and right upper-quadrant pain.
- Serious blood disorders such as agranulocytosis, aplastic anaemia or severe thrombocytopenia.
Not Known
Frequency cannot be estimated from available data
- Any unusual or unexpected symptom that cannot be attributed to another cause; post-marketing surveillance continuously refines the known safety profile.
Most side effects of Qaialdo are mild, short-lived and self-resolving. They typically occur during the first days or weeks of treatment and improve as the body adjusts to the medication. Taking Qaialdo with food (where permitted), staying well hydrated, rinsing the mouth after dosing and avoiding alcohol can help reduce gastrointestinal and mucosal side effects.
In contrast, a small number of side effects are potentially serious and require immediate medical attention. Stop taking Qaialdo and seek emergency care if you notice any of the following:
- Difficulty breathing, wheezing, throat tightness or facial/tongue swelling.
- Sudden widespread rash, blistering or peeling of the skin, or painful mouth ulcers.
- Yellowing of the skin or eyes (jaundice), very dark urine or pale stools.
- New bleeding or bruising, persistent fever, sore throat or unusual fatigue.
- Severe chest pain, irregular heartbeat, fainting or convulsions.
- New or worsening thoughts of self-harm or suicide.
How to Report Side Effects
Reporting side effects helps health authorities monitor the safety of medicines and can ultimately protect other patients. If you experience any unwanted reaction, tell your doctor, pharmacist or nurse – including effects not listed in the patient information leaflet. You can also report side effects directly to your national pharmacovigilance programme (for example the EMA's European database of suspected adverse drug reaction reports, the U.S. FDA MedWatch programme, the UK's Yellow Card Scheme, Swissmedic's Vigibase portal or the Australian Therapeutic Goods Administration's Adverse Event Management System). Provide as much detail as possible: the suspected medicine (Qaialdo), the dose taken, the time between administration and symptoms, and any other medicines you were taking at the same time.
How Should You Store Qaialdo?
Correct storage preserves the chemical stability and microbiological quality of Qaialdo. Oral suspensions are especially sensitive to temperature, light and microbial contamination because they contain water, sugars and other nutrients that can support the growth of bacteria and fungi once the bottle is opened. Follow the storage instructions printed on the carton and repeated in the leaflet. General principles include:
- Temperature: Store at the temperature stated on the carton – typically below 25 °C or 30 °C, or in the refrigerator at 2–8 °C, depending on the product. Do not freeze unless explicitly permitted; freezing can break the suspension and damage the active substance.
- Light and moisture: Keep the bottle in its original outer carton, with the label facing outwards so that the expiry date and lot number remain readable. Avoid storage in humid areas such as bathrooms and above sinks.
- Upright storage: Keep the bottle standing upright to prevent leakage through the cap and to maintain a uniform suspension.
- Child safety: Store out of the sight and reach of children. Use a locked cupboard if small children or cognitively impaired adults live in the household. Never describe the medicine as "sweets" or "juice".
- Expiry date: Do not use Qaialdo after the expiry date (EXP) printed on the carton and bottle. The expiry date refers to the last day of the stated month.
- In-use shelf life: Once the bottle is opened, the active ingredient may remain stable only for a defined period (often 14, 28 or 30 days) – record the date of first opening on the carton and discard the bottle when the in-use period ends, even if suspension remains.
- Inspect before use: If the suspension looks discoloured, smells unusual, contains clumps that do not disperse after vigorous shaking, or if the bottle is leaking, damaged or has been tampered with, do not use it. Return the bottle to the pharmacy.
- Disposal: Do not pour Qaialdo down sinks or toilets and do not put it in household rubbish. Return unused or expired medicine to a pharmacy or authorised take-back scheme for safe environmental disposal.
When travelling with Qaialdo, keep the bottle in its original carton in your hand luggage rather than checked baggage to avoid temperature extremes. If the product requires refrigeration, transport it in an insulated bag with a cold pack and plan ahead for refrigeration at your destination. Bring a copy of your prescription and a letter from your doctor if you are crossing borders, as this simplifies customs and security checks.
If a child or a non-prescribed person swallows Qaialdo, call your local emergency number or poison information centre immediately, even if the person appears well. Keep the bottle and carton with you so that the medical team can identify the product, the strength (10 mg/ml) and the volume involved. Do not induce vomiting unless specifically instructed to do so by a healthcare professional.
What Does Qaialdo Contain?
Every medicinal product contains both an active substance and a series of inactive ingredients (excipients) that are essential for pharmaceutical performance. Knowing these ingredients is important if you have allergies, metabolic disorders or dietary restrictions, or if you are following a low-sugar, low-sodium or alcohol-free regimen. Below is a structured overview of the typical composition of an oral suspension like Qaialdo.
Active Ingredient
The active substance of Qaialdo is the pharmacologically active compound responsible for the medicine's therapeutic effect. It is present at a concentration of 10 mg per millilitre of suspension. The exact chemical name, molecular formula and pharmacological classification of the active substance are stated in the Summary of Product Characteristics and the leaflet inside each carton.
Inactive Ingredients (Excipients)
| Excipient Role | Common Examples | Purpose in the Formulation |
|---|---|---|
| Suspending / viscosity agent | Xanthan gum, hydroxyethylcellulose, microcrystalline cellulose, carrageenan | Keeps the solid active particles evenly distributed in the liquid and prevents rapid settling between shakes. |
| Wetting agent / surfactant | Polysorbate 80, poloxamer | Helps the active substance mix with water and resist clumping. |
| Sweetener | Sucrose, sorbitol, glycerol, sucralose, saccharin | Improves palatability, especially important for paediatric patients. |
| Flavouring | Strawberry, banana, orange, raspberry, vanilla flavours | Masks bitter or metallic taste of the active ingredient. |
| Preservative | Sodium benzoate, potassium sorbate, methyl- and propyl-parabens | Prevents growth of bacteria, yeasts and moulds after the bottle is opened. |
| pH buffer | Citric acid, sodium citrate, phosphate buffers | Maintains the pH within the range where the active substance is most stable and best tolerated. |
| Colouring agent | Titanium dioxide, carotene, approved food dyes | Gives the suspension a uniform, recognisable appearance (only used when regulatory authorities permit it). |
| Vehicle | Purified water, sometimes glycerol or propylene glycol | The liquid base in which the active ingredient and other excipients are dispersed. |
If you have a known allergy or intolerance to any of these excipient classes (for example, paraben hypersensitivity, fructose intolerance, aspartame sensitivity or propylene glycol reactions), consult the exact excipient list in the Qaialdo Patient Information Leaflet before taking the product for the first time. Your pharmacist can help you identify any ingredient that may be incompatible with your medical history or dietary preferences.
Appearance and Pack Sizes
Qaialdo oral suspension is supplied in a light-protective bottle, typically made of amber glass or opaque plastic. The bottle contains a measured volume of suspension (for example 100 ml, 150 ml or 200 ml) and is packed in a cardboard carton together with the Patient Information Leaflet and, in most markets, a calibrated oral syringe and a bottle adaptor. Not all pack sizes are marketed in every country.
Marketing Authorisation Holder and Manufacturer
The name and address of the marketing authorisation holder, the manufacturer(s) and the national representatives of the Qaialdo product are printed on the carton and in the Patient Information Leaflet. If you have a question about the quality of the product, the batch number or a suspected defect, contact the marketing authorisation holder directly or ask your pharmacist to do so on your behalf.
Frequently Asked Questions About Qaialdo
Qaialdo is a prescription-only (Rx) oral suspension supplied at a strength of 10 mg per millilitre. It is dispensed by a doctor for the specific condition identified in your individual prescription. Because Qaialdo is available only with a prescription, the exact indication, treatment duration and target patient group are determined by the prescribing physician based on your diagnosis, medical history and treatment goals. Always refer to your personal patient information leaflet and follow the instructions given by your healthcare provider for the authorised use in your country.
Qaialdo is a liquid oral suspension containing 10 milligrams of active substance per millilitre. The dose is usually prescribed in millilitres (ml) and must be measured with the oral syringe, dosing cup or measuring spoon supplied with the medicine. Household teaspoons are not accurate and should never be used. Always shake the bottle well for at least 10 seconds before each dose to redistribute the suspended particles evenly, so that every millilitre contains the correct amount of active ingredient. Give the dose slowly into the side of the mouth and offer a small drink of water afterwards.
Side effects depend on the specific active substance and dose prescribed. Oral suspensions in general can cause gastrointestinal effects such as nausea, abdominal discomfort, altered taste or loose stools, particularly during the first days of treatment. Serious or unexpected reactions – for example rash, swelling of the face or throat, difficulty breathing, persistent vomiting or marked changes in behaviour or consciousness – require immediate medical evaluation. Report any unusual symptoms to your prescriber so they can decide whether Qaialdo should be continued, adjusted or stopped.
Do not start Qaialdo during pregnancy, when planning pregnancy, or during breastfeeding without first discussing it with your doctor. Your prescriber will assess whether the expected benefit of treatment outweighs any potential risk to the foetus or the nursing infant, taking into account the specific active substance, the dose, your clinical condition and alternative treatment options. If you become pregnant while using Qaialdo, inform your doctor as soon as possible rather than stopping treatment on your own.
Store Qaialdo according to the instructions on the bottle label and patient information leaflet, typically at controlled room temperature below 25–30 °C, away from direct sunlight, moisture and heat. Some oral suspensions require refrigeration (2–8 °C) and may have a limited in-use shelf life (for example 14, 28 or 30 days) once the bottle has been opened. Keep the bottle tightly closed, out of the sight and reach of children, and never transfer the medicine to another container. Do not use Qaialdo after the expiry date printed on the carton or beyond the in-use period defined by the manufacturer.
Like all prescription medicines, Qaialdo has the potential to interact with other drugs, herbal products and certain foods. Interactions may either increase the risk of side effects or reduce the effectiveness of your treatment. Before starting Qaialdo, tell your doctor and pharmacist about every prescription medicine, over-the-counter product, vitamin, herbal remedy and dietary supplement you are using, including any recent or planned changes. Do not start or stop any other medication during Qaialdo treatment without first asking a healthcare professional.
Qaialdo is a suspension, not a solution, which means the active ingredient is present as fine solid particles dispersed in the liquid rather than fully dissolved. Between doses, gravity causes these particles to settle towards the bottom of the bottle. If you do not shake the bottle, the first doses from a settled bottle will contain too little active substance (and may not work), while the last doses will contain too much (and can increase side effects). Shake vigorously for at least 10–15 seconds before every dose to ensure that each millilitre contains the correct 10 mg of active ingredient.
References
- European Medicines Agency (EMA). Guideline on Pharmaceutical Development of Medicines for Paediatric Use. 2013. Available at: EMA Paediatric Development Guideline.
- European Medicines Agency (EMA). Product Information Template for Human Medicines (Summary of Product Characteristics, Labelling and Package Leaflet). Quality Review of Documents (QRD). 2024.
- U.S. Food and Drug Administration (FDA). Guidance for Industry: Labeling for Human Prescription Drug and Biological Products – Implementing the PLR Content and Format Requirements. Silver Spring, MD: FDA; 2024.
- U.S. Food and Drug Administration (FDA). Medication Errors Related to Drugs Subject to the Pediatric Dosing Provisions: Oral Liquid Dosage Forms. FDA Drug Safety Communication. 2023.
- British National Formulary (BNF) and BNF for Children (BNFc). National Institute for Health and Care Excellence (NICE). 2025.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Available at: WHO Essential Medicines List.
- World Health Organization (WHO). Promoting Safety of Medicines for Children. Geneva: WHO; 2020.
- Ernest TB, Elder DP, Martini LG, Roberts M, Ford JL. Developing Paediatric Medicines: Identifying the Needs and Recognizing the Challenges. J Pharm Pharmacol. 2007;59(8):1043–1055. doi:10.1211/jpp.59.8.0002.
- Standing JF, Tuleu C. Paediatric Formulations – Getting to the Heart of the Problem. Int J Pharm. 2005;300(1–2):56–66. doi:10.1016/j.ijpharm.2005.05.006.
- Yin HS, Parker RM, Sanders LM, et al. Liquid Medication Errors and Dosing Tools: A Randomized Controlled Experiment. Pediatrics. 2016;138(4):e20160357. doi:10.1542/peds.2016-0357.
- National Institute for Health and Care Excellence (NICE). Medicines Optimisation: The Safe and Effective Use of Medicines to Enable the Best Possible Outcomes. NICE Guideline NG5. London: NICE; 2024.
- Council of Europe. European Pharmacopoeia, 11th Edition – Monograph on Oral Liquid Preparations. Strasbourg: EDQM; 2024.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in clinical pharmacology, internal medicine and paediatrics with extensive experience in medication safety and the use of oral liquid formulations.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, BNF, NICE).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.